CompletedNot Applicable

Efficacy of IVIG Versus PLEX in Myasthenic Crisis in Syria.

Syria50 participantsStarted 2022-09-01

Plain-language summary

This study compares the clinical effectiveness of Intravenous Immunoglobulin (IVIG) versus Plasma Exchange (PLEX) in patients experiencing a myasthenic crisis. Clinical response is evaluated 14 days post-treatment using the Quantitative Myasthenia Gravis Score (QMG). Additionally, the study aims to identify and report common precipitating factors for myasthenic attacks, such as respiratory infections or surgical stress.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Confirmed Diagnosis: Patients with newly diagnosed or previously confirmed Myasthenia Gravis (MG) based on clinical evaluation and confirmed by electromyography (EMG). * Severity: Patients presenting with myasthenic crisis or severe exacerbation. * Age: 18 years and older. * Treatment Necessity: Patients requiring rapid immunomodulating therapy (either IVIG or PLEX). * Informed Consent: Participants or their legal guardians must be able and willing to provide written informed consent. Exclusion Criteria: * Medical Contraindications: Severe renal failure (contraindication for IVIG) or hemodynamic instability (contraindication for PLEX). * Alternative Conditions: Presence of other neuromuscular disorders or congenital myasthenia. * Pregnancy: Pregnant or breastfeeding women. * Consent: Inability to provide informed consent.

What they're measuring

Mean Change from Baseline in the Quantitative Myasthenia Gravis (QMG) Score

Timeframe: Day 14 post-initiation of treatment

Trial details

NCT IDNCT07532707

SponsorDamascus University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-10-15

View on ClinicalTrials.gov More Myasthenic Crisis trials